Could ACP3 PET help address some of the limitations of PSMA in prostate cancer imaging and therapy?
In this EMUC TV video, Prof. Philipp Backhaus discusses the potential of ACP3 as a novel theranostic target across multiple stages of prostate cancer. Drawing on first-in-human imaging and treatment experience, he explains how ACP3 PET may reveal additional lesions not detected by PSMA PET, improve disease characterization, and help identify patients who could benefit from targeted radioligand therapies. The video also explores the complementary roles of ACP3 and PSMA, the unmet clinical needs in prostate cancer imaging, and the next steps in clinical development of ACP3-based theranostics.